⊥Lucigen Corporation, Middleton, Wisconsin 53562, United States.
J Nat Prod. 2015 Apr 24;78(4):924-8. doi: 10.1021/np500911k. Epub 2015 Mar 10.
Bioassay-guided fractionation of the organic extracts of a Bacillus amyloliquefaciens strain (AP183) led to the discovery of a new macrocyclic polyene antibiotic, bacillusin A (1). Its structure was assigned by interpretation of NMR and MS spectroscopic data as a novel macrodiolide composed of dimeric 4-hydroxy-2-methoxy-6-alkenylbenzoic acid lactones with conjugated pentaene-hexahydroxy polyketide chains. Compound 1 showed potent antibacterial activities against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium with minimum inhibitory concentrations in a range of 0.6 to 1.2 μg/mL. The biosynthetic significance of this unique class of antibiotic compounds is briefly discussed.
生物活性导向分离一株解淀粉芽孢杆菌（AP183）的有机提取物，发现了一种新的大环多烯类抗生素，芽孢菌素 A（1）。通过对 NMR 和 MS 光谱数据的解析，其结构被确定为一种新型的大环二内酯，由二聚体 4-羟基-2-甲氧基-6-烯基苯甲酸内酯与共轭戊烯-六羟基聚酮链组成。化合物 1 对耐甲氧西林金黄色葡萄球菌和万古霉素耐药粪肠球菌表现出很强的抗菌活性，最低抑菌浓度范围为 0.6 至 1.2 μg/mL。简要讨论了这类具有独特结构的抗生素化合物的生物合成意义。
